scholarly article | Q13442814 |
P50 | author | Erik Thunnissen | Q42770142 |
Andrew Dodson | Q89226273 | ||
P2093 | author name string | David Allen | |
Anthony O'Grady | |||
Keith Miller | |||
Jamie Hughes | |||
Suzanne Parry | |||
Birgit Lissenberg-Witte | |||
Alex Haragan | |||
Emma McClean | |||
P2860 | cites work | Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer | Q34989083 |
Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma | Q36382143 | ||
Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch | Q37708016 | ||
Principles of analytic validation of immunohistochemical assays: Guideline from the College of American Pathologists Pathology and Laboratory Quality Center | Q38197280 | ||
Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer | Q38376439 | ||
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma | Q38742013 | ||
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas | Q39623256 | ||
Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms | Q41348743 | ||
PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study | Q47103927 | ||
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, an | Q47642815 | ||
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer | Q47834638 | ||
Microarray as a model for quantitative visualization chemistry. | Q47871523 | ||
Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer | Q49635725 | ||
Multicenter French harmonization study for PD-L1 IHC testing in non-small cell lung cancer | Q49916859 | ||
PD-L1 IHC in NSCLC with a global and methodological perspective | Q50127658 | ||
Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples | Q50347895 | ||
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. | Q52586557 | ||
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q57051777 | ||
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project | Q57272453 | ||
How to Validate Predictive Immunohistochemistry Testing in Pathology?: A Practical Approach Exploiting the Heterogeneity of Programmed Death Ligand-1 Present in Non-Small Cell Lung Cancer | Q57279680 | ||
Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods | Q88242252 | ||
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q90310971 | ||
Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimen | Q91537629 | ||
A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project | Q91553291 | ||
Impact of delayed fixation and decalcification on PD-L1 expression: a comparison of two clones | Q91566534 | ||
The impact of crosslinking and non-crosslinking fixatives on antigen retrieval and immunohistochemistry | Q91976328 | ||
In Reply | Q95568790 | ||
P433 | issue | 2 | |
P304 | page(s) | 138-145 | |
P577 | publication date | 2019-12-17 | |
P1433 | published in | The journal of pathology. Clinical research | Q27726530 |
P1476 | title | External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different | |
P478 | volume | 6 |
Search more.